102 TCOG102 11 01

*

*

10231102331

https://pfp.bhp.doh.gov.tw48*

*

*

3055305(12:30-13:20)3004020

102*

1025101918=94.74%738.89% 844.44% 316.67%*

-1

2

*

*

N%211.11 1688.89

*

N%00.0018100.00N=171617131191

*

N%1266.67633.33 SOP

*

N%211.111688.89844.44738.89TCOG316.67 1372.22 00.00 527.78 32

-2

?*

*

N%00.0018100.003N=1771715

*

N%3015.56 1794.44 3001688.89 211.11

*

N%2015.561794.44

1794.4415.56

*

N%738.891055.5615.56211.111688.89

*

*

4 (1 )1 6 1 17 6 6 1 2 1 1 36 10 2

*

Rating A 10Rating A + Rating B 26 Rating D + Rating E0 10 Rating B 5 Rating A Rating A + Rating B > 10 Rating D 3 Rating E0 Rating A + Rating B 10 Rating D 4 Rating E 1

()

B

1.22.43.23.3.33.53.6.23.6.33.104.15.1*

*

*

*

1.1Rating ERating DRating C50

*

1.1Rating BC Rating AB1.275 %

*

1.1

*

1.1

1.1*()

*

1.2 1234

*

1.2 Rating ERating DRating C Rating CRating BC

*

1.2 Rating AB 1 ~ 4

*

1.2

1.2*)

*

1.3 Rating ERating DRating CRating CRating BCPDCARating ABPDCA

*

1.312

1.3*

*

1.4 1AJCC 23 4

*

1.4 1. 1AJCC 23

*

1.4

1.4*

*

*

2.1Rating ERating DRating DRating CRating BC

*

2.1Rating AB3000130002

*

*

2.1 102 99

2.1 *

*

2.2Rating ERating DRating D95%98%90%95%Rating C98%95%98%Rating B98%98%95%Rating A98

*

2.2( 97 -9999100(1)( A / B ) 100%100A98B98 + 98

*

2.2(2)E+F/ D 100% (100)D98E9898F9898

*

2.2(3)G / H 100%100G98H98

2.

*

2.3Rating ERating DRating CRating CRating B C Rating A B

*

2.3

*

2.3Rating A 3 123

2.3 *

*

2.4 Rating ERating DRating CRating CRating BCRating AB

*

2.4 1234Class1~25

2.4*

*

2.5Class1~2Rating E Rating DRating C Rating C80

*

2.5Rating BC80 ~ 95%Rating AB 95%

*

2.5Class 1~ 2Stage

*

2.5123 Class 1~245

*

2.5K / L 100 K L 10%Class 1~2

*

962.13Tumor Size96983.4T Clinical T1151172.14Regional Lymph Nodes Examined991003.5N Clinical N1181192.15Regional Lymph Nodes Positive1011023.6M Clinical M1201213.7Clinical Stage Group122124

*

3.10T Pathologic T127129Other Staging System FIGO3.11N Pathologic N130131Other Staging SystemBCLC1013.12M Pathologic M1321333.13Pathologic Stage Group134136Other Staging Systemhistology101

2.52.4*

*

2.6 Class 0 ~ 3Rating ERating DRating CRating BCRating AB

*

2.61Class 0~32Class 1~2 2 5Class 0334:56

2.6

*

*

*

3.1Rating ERating DRating CRating CRating BC

*

3.1Rating AB /

*

3.11 peer review article234

*

3.1Rating A Hodgkin lymphomaBDiffuse large B cell lymphoma Follicular lymphoma

3.1*

*

3.2 Rating ERating DRating CRating C70 %Rating BC50%

*

3.2 Rating ABClass 1~2

*

3.2 Class 1~21 22

3

1,000 61,001~2,00092,001 12

*

3.2 123minimum requirement12345comorbidity6regimensdose

*

3.2 C Bsummary note

3.2 regimenRTdose *

*

3.3 3.3.1 Rating E20 %Rating D20 %40 %Rating C40 %60 %Rating B60 %80 %Rating A80 %

*

3.3.112T NM AJCC

*

3.3.1

1272411 [ ( 27 + 14 + 01 ) / ( 212 ) ] 100 %18 / 24 100 %75 %Rating B3.2

3.3.1

*

*

3.3.2 Rating E20 %Rating D20 %40 %Rating C40 %60 %Rating B60 %80 %Rating A80 %

*

3.3.2123

*

3.3.2

12833211 [ ( 38 + 23 + 11 ) / ( 312 ) ] 100 %31 / 36 100 %86 %Rating A3.2

3.3.2 *

*

3.3.3 Rating E20 %Rating D20 %40 %Rating C40 %60 %Rating B60 %80 %Rating A80 %

*

3.3.3 123Neoadjuvant

*

3.3.3

94322 211 [ ( 34 + 22 + 12 + 01 ) / ( 39 ) ] 100 %18 / 27 100 %67 % Rating B 3.2

3.3.3*1.

*

3.3.4Rating E20 %Rating D20 %40 %Rating C40 %60 %Rating B60 %80 %Rating A80 % curative intent

*

3.3.4curative intent123 1 13 C

*

3.3.41.

92 332311 [ ( 32 + 23 + 13 + 01 ) / ( 39 ) ] 100 %15 / 27 100 %56 % Rating C2. 3.2

3.3.4 *

*

3.4Rating ERating DRating CRating CRating BC70 %

*

3.4Rating AB

*

3.4

*

3.424B1502

*

1. 2. 3. 4. 5. 6. ()

*

7. 8. 9. 10. 11. 12.

3.4

*

*

3.5 Rating ERating DRating CRating C10%

*

3.5 Rating BC10%5%Rating AB10%20%10%

*

3.5 Class 1~3

*

3.5 12303123

*

3.5 1234

*

3.5 1 conclusion or recommendation 2 process

3.5 10%50%*

*

3.63.6.1Rating ERating DRating CRating C

*

3.6.1Rating BCRating AB

*

3.6.1AdjuvantNeoadjuvantConcurrent Chemoradiotherapy CCRT

*

3.6.1*

*

3.6.2 Rating ERating DRating CRating C 3.6.1 prescriptionRating BCprescriptionRating AB

*

3.6.2 1.prescription

3.6.2

*

*

3.6.3 Rating ERating DRating CRating CRating BCRating AB

*

3.6.3

*

3.6.3 123

*

3.6.3

*

3.6.3 (spill kits)1

Class II BClass III

*

3.6.3 2

3.6.3

*

*

3.6.4 Rating ERating DRating CRating CRating BCRating AB

*

3.6.412

*

3.6.4

*

3.6.43.6.3 1

3.6.4 *

*

3.73.7.1Rating ERating DRating CRating C

*

3.7.1Rating BCRating AB

*

3.7.112 permanent section Her-2 /neuCAPTAFISO15189

3.7.1

*

*

3.7.2Rating ERating DRating CRating CRating BC

*

3.7.2Rating AB

3.7.2

*

*

3.8 Rating E Rating DRating CRating CRating BC

*

3.8Rating AB

*

3.8 CT MRI

3.8

*

*

3.9Rating ERating DRating CRating C (curative intent) Rating BCRating C (curative intent)

*

3.9Rating ABRating C curative intent

*

3.9 12CTVPTV

*

3.91peer review article234

*

3.912CC E

3.9(:) *

*

3.10 Rating ERating DRating CRating CRating BRating A

*

3.10 102

3.10 *

*

*

4.1 123 / 4Rating E

Rating DRating C

*

4.1 Rating CRating BCRating AB

*

4.1 /Port-AHickmanPICC /

*

4.1 3.6.4

4.1

*

*

4.2 Rating E Rating DRating CRating C Rating BC Rating AB

*

4.23.6.4

4.2

*

*

4.3 Rating ERating DRating CRating CRating BRating A

*

4.3

*

4.3 1.3 3 41 3.6.4

4.3*

*

4.4Rating E Rating DRating CRating C

*

4.4Rating BC20 8020Rating AB 6 50%

*

4.420

*

4.4 6 6 6

4.4850%

*

*

4.5Rating ERating DRating CRating C50Rating BCClass1~2400

*

4.5Rating AB10299

*

4.511 2 234 C

4.5*

*

4.6 Rating ERating DRating CRating CRating BC

*

4.6Rating AB

*

4.6()

*

4.6 A intake BMI

4.6*

*

*

5.1 Rating ERating DRating C Rating CRating B CRating A B

*

5.1 2 PDCA

5.1 2

*

*

5.2 Rating ERating DRating CRating BCRating AB

*

5.2

*

*

6.1 Class1~22,000AIRBClass1~22,0001A

*

6.1 IRB

6.1(:) *

*

*